Daily Record Staff//September 15, 2015
//September 15, 2015
AgeneBio, a Baltimore-based biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.
The five-year grant, estimated at $7.5 million, initiates a public-private partnership among the NIH’s National Institute on Aging, Johns Hopkins University and AgeneBio to study AGB101and its potential to prevent or delay the onset of Alzheimer’s dementia.
The HOPE4MCI Phase 3 trial is the first and only trial to reduce hippocampal overactivity during amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s, and is expected to begin in early 2016.